Arcadia Biosciences Q1 2024 GAAP EPS $(1.78) Beats $(2.52) Estimate, Sales $1.255M Beat $1.194M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcadia Biosciences (NASDAQ:RKDA) reported Q1 2024 earnings with a GAAP EPS of $(1.78), surpassing the $(2.52) estimate, and sales of $1.255M, exceeding the $1.194M estimate. This represents a significant improvement over the previous year, with an 83.61% increase in EPS and a 1.87% increase in sales.
May 09, 2024 | 8:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcadia Biosciences reported a notable improvement in Q1 2024 earnings, with EPS and sales beating estimates and showing significant year-over-year growth.
Beating both EPS and sales estimates indicates a strong financial performance and operational efficiency, likely leading to positive investor sentiment and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100